72209-88-2

Upstream product

• 104-81-4 4-Methylbenzyl bromide 
• 17356-08-0 thiourea 

Downstream Products

• 73553-21-6 (4-methylbenzyl)(pent-4-en-1-yl)sulfane 
• 14310-20-4 4-methylbibenzyl 
• 1253654-42-0 N-{4-methyl-2-[(4-methylbenzyl)sulfanyl]-6-oxo-1,6-dihydropyrimidin-5-yl}benzamide 
• 1253654-58-8 N-{4-ethyl-2-[(4-methylbenzyl)sulfanyl]-6-oxo-1,6-dihydropyrimidin-5-yl}benzamide 
• 1253654-20-4 N-{2-[(4-methylbenzyl)sulfanyl]-6-oxo-1,6-dihydropyrimidin-5-yl}benzamide 
• 20193-94-6 bis-(4-methyl-benzyl)-disulfide 
• 4498-99-1 4-methylbenzylthiol 

Relevant academic research and scientific papers

Synthesis of difluoromethyl and deuterium-labeled difluoromethyl thioethers from aliphatic electrophiles

A one-pot difluoromethylthiolation of alkyl electrophiles with thiourea and diethyl bromodifluoromethylphosphonate is described. The transition-metal-free approach, readily available reagents, and mild conditions provide a practical way for the synthesis of difluoromethyl thioethers. By changing the "H" source to the most commonly used "D" sources CD3OD and D2O, this strategy enables efficient synthesis of SCF2D-substituted molecules in good yields with high levels of D incorporation.

4- (SULFANYL-PYRIMIDIN-4-YLMETHYL) -MORPHOLINE DERIVATIVES AND RELATED COMPOUNDS AS GABA RECEPTOR LIGANDS FOR THE TREATMENT OF ANXIETY, DEPRESSION AND EPILEPSY

The present invention relates to compounds of Formula (I) wherein X is-S-or-NH-; R1 is alkyl, alkenyl, arylalkyl, arylalkenyl or aryl-O-alkyl, wherein the aryl groups are optionally substituted by one or more substituents, selected from the group consisting of lower alkyl, lower alkoxy, halogen or lower halogen-alkyl; R2 is hydrogen, lower alkyl or cycloalkyl; R3 /R4 may form together with the N-atom to which they are attached a non aromatic5, 6 or 7 membered ring, which may contain in addition to the N-atom one additional heteroatom selected from the group consisting of O, S or N, and wherein the ring is optionally substituted by hydroxy, lower alkyl, lower alkoxy,-NR2,-CONR2,-CO-lower alkyl or benzyl; or may form together with the N-atom to which they are attached a heterocyclic ring system, containing at least two rings and which may contain one or two additional heretoatoms, selected from the group consisting of N or O; R is hydrogen or lower alkyl; R5 is hydrogen or lower alkyl; and to pharmaceutically suitable acid addition salts thereof. It has been found that the compounds are active on the GABAB receptor and therefore useful for the treatment of anxiety, depression, epilepsy, schizophrenia, cognitive disorders, spasticity and skeletal muscle rigidity, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, cerebral palsy, neuropathic pain and craving associated with cocaine and nicotine, psychosis, panic disorder, posttraumatic stress disorders or gastro-intestinal disorders.